pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics clinical programs — 12 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 256 E Grand Ave, Suite 104, South San Francisco, California 94080, US
- Employees
- 103
- Programs
- 34
- Drugs
- 14
- Patents
- 1
BridgeBio Oncology Therapeutics projects
12 ClinicalTrials.gov programs sponsored by BridgeBio Oncology Therapeutics.
BridgeBio Oncology Therapeutics has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AG10 oral tablet
BridgeBio Oncology Therapeutics
Amyloid Cardiomyopathy, Transthyretin-Related
1 trial -
BBO-10203
BridgeBio Oncology Therapeutics
Solid Tumor, Adult
1 trial -
BBO-11818
BridgeBio Oncology Therapeutics
Non-Small Cell Lung Cancer
1 trial -
BBO-8520
BridgeBio Oncology Therapeutics
Non-small Cell Lung Cancer
1 trial -
BBP-398
BridgeBio Oncology Therapeutics
Solid Tumor, Adult
1 trial -
BBP-398 (Formerly known as IACS-15509)
BridgeBio Oncology Therapeutics
Tumor, Solid
1 trial -
BBP-398 with nivolumab
BridgeBio Oncology Therapeutics
Non Small Cell Lung Cancer
1 trial -
BBP-671
BridgeBio Oncology Therapeutics
Healthy Volunteers
1 trial -
BBP-711
BridgeBio Oncology Therapeutics
Healthy
1 trial -
Infigratinib
BridgeBio Oncology Therapeutics
Bladder Transitional Cell Carcinoma
1 trial -
Infigratinib
BridgeBio Oncology Therapeutics
Breast Cancer
1 trial -
Infigratinib
BridgeBio Oncology Therapeutics
Glioma
1 trial
Frequently asked questions
How many clinical projects does BridgeBio Oncology Therapeutics have?
12 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.